Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | SUITE 310, 815 W. HASTINGS STREET VANCOUVER BC V6C 1B4 |
Tel: | N/A |
Website: | https://www.inmedpharma.com |
IR: | See website |
Key People | ||
Eric A. Adams President, Chief Executive Officer, Director | N. Netta Jagpal Chief Financial Officer, Corporate Secretary | Michael Henry Woudenberg Chief Operating Officer |
Eric Chih-Hsien Hsu Senior Vice President - Preclinical Research and Development | Alexandra D.J. Mancini Senior Vice President - Clinical and Regulatory Affairs |
Business Overview |
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma. |
Financial Overview |
For the six months ended 31 December 2023, InMed Pharmaceuticals Inc revenues increased from $791K to $2.1M. Net loss decreased 28% to $4M. Revenues reflect BayMedica segment increase from $470K to $2.1M. Lower net loss reflects General and administrative - Balancing v decrease of 11% to $2.4M (expense), Research and development and patents - B decrease of 12% to $1.9M (expense). |
Employees: | 13 as of Jun 30, 2020 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $5.49M as of Dec 31, 2023 |
EBITDA (TTM): | -$6.78M as of Dec 31, 2023 |
Net annual income (TTM): | -$6.35M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.50M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 6,056,970 as of Feb 13, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |